TY  - GEN
AU  - Heijerman,Harry G M
AU  - McKone,Edward F
AU  - Downey,Damian G
AU  - Van Braeckel,Eva
AU  - Rowe,Steven M
AU  - Tullis,Elizabeth
AU  - Mall,Marcus A
AU  - Welter,John J
AU  - Ramsey,Bonnie W
AU  - McKee,Charlotte M
AU  - Marigowda,Gautham
AU  - Moskowitz,Samuel M
AU  - Waltz,David
AU  - Sosnay,Patrick R
AU  - Simard,Christopher
AU  - Ahluwalia,Neil
AU  - Xuan,Fengjuan
AU  - Zhang,Yaohua
AU  - Taylor-Cousar,Jennifer L
AU  - McCoy,Karen S
TI  - Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
SN  - 1474-547X
PY  - 2019///1206
KW  - Adolescent
KW  - Aminophenols
KW  - administration & dosage
KW  - Benzodioxoles
KW  - Child
KW  - Chloride Channel Agonists
KW  - Cystic Fibrosis
KW  - drug therapy
KW  - Cystic Fibrosis Transmembrane Conductance Regulator
KW  - genetics
KW  - Double-Blind Method
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Male
KW  - Pyrazoles
KW  - Pyridines
KW  - Pyrrolidines
KW  - Quinolones
KW  - Sweat
KW  - chemistry
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S0140-6736(19)32597-8
ER  -